Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
3 HRH3 [1] Neuroactive ligand-receptor interaction D09870 Bavisant [1] 6
4 HRH3 [1] Neuroactive ligand-receptor interaction D10749 Pitolisant [3] 6, 113, 193
5 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [1] 6
6 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
7 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
8 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide [1] 6
9 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
10 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00525 Pilocarpine [3] 6, 53, 299
11 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D07226 Fesoterodine [1] 6
12 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
13 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [1] 6
14 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
15 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00525 Pilocarpine [3] 6, 53, 299
16 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin [2] 6, 13
17 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D07226 Fesoterodine [1] 6
18 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin [3] 6, 13, 53
19 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
20 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide [1] 6
21 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
22 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
23 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [1] 6
24 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
25 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
26 CHRNA1 [2] Virion - Lyssavirus, Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
27 CHRNA2 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
28 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
29 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
30 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [3] 6, 18, 53
31 CHRNA5 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
32 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
33 CHRNB1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
34 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
35 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [3] 6, 18, 53
36 CHRNB3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
37 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
38 CHRND [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
39 CHRNE [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
40 CHRNG [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
41 CLCN2 [1] Mineral absorption D04790 Lubiprostone [4] 6, 13, 290, 299
42 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05099 Nabilone [3] 6, 13, 127
43 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol [20] 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
44 CNR2 [1] Neuroactive ligand-receptor interaction D05099 Nabilone [3] 6, 13, 127
45 CNR2 [1] Neuroactive ligand-receptor interaction D10915 Cannabidiol [19] 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
46 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00781 Entacapone [2] 6, 17
47 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00786 Tolcapone [3] 6, 28, 127
48 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D10825 Opicapone [1] 6
49 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
50 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
51 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
52 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
53 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D04641 Istradefylline [1] 6
54 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D09717 Preladenant [1] 6
55 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D10174 Tozadenant [1] 6
56 CSF2RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D05803 Sargramostim [7] 6, 28, 60, 62, 96, 229, 285
57 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim [35] 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
58 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
59 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
60 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
61 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
62 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
63 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
64 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
65 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
66 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
67 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
68 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
69 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
70 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
71 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
72 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
73 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
74 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
75 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
76 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
77 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
78 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
79 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
80 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
81 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
82 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
83 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
84 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
85 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
86 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
87 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
88 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
89 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol [1] 6
90 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa [5] 5, 6, 17, 169, 170
91 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin [1] 6
92 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
93 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol [1] 6
94 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
95 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol [1] 6
96 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
97 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol [5] 1, 2, 6, 13, 256
98 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
99 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
100 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
101 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
102 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron [4] 6, 13, 53, 226
103 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril [8] 6, 17, 46, 86, 96, 97, 107, 271
104 DDC [9] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D00558 Carbidopa [7] 6, 13, 17, 90, 140, 164, 201
105 DDC [9] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D03082 Benserazide [1] 6
106 HTR3C [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
107 HTR3C [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [3] 6, 97, 107
108 HTR3C [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
109 NQO1 [7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D08682 Warfarin [11] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91
110 DPP4 [1] Protein digestion and absorption D08516 Sitagliptin [4] 6, 75, 233, 299
111 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
112 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D07460 Apomorphine [3] 5, 6, 7
113 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D07870 Dopamine [4] 6, 7, 74, 299
114 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D08339 Pergolide [1] 6
115 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D11431 Tavapadon [1] 6
116 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D11839 Foslevodopa [1] 6
117 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
118 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00987 Cabergoline [3] 6, 74, 75
119 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01164 Aripiprazole [2] 6, 206
120 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01226 Sulpiride [2] 6, 70
121 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01745 Domperidone [5] 6, 13, 17, 51, 230
122 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D02666 Iloperidone [1] 6
123 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D03165 Bromocriptine [2] 6, 74
124 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D05575 Pramipexole [3] 2, 6, 20
125 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D05768 Rotigotine [1] 6
126 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07305 Piribedil [1] 6
127 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07309 Melperone [1] 6
128 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07460 Apomorphine [3] 5, 6, 7
129 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07593 Buspirone [2] 6, 51
130 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07868 Domperidone [5] 6, 13, 17, 51, 230
131 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07870 Dopamine [4] 6, 7, 74, 299
132 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08132 Lisuride [2] 6, 86
133 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08339 Pergolide [1] 6
134 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08456 Quetiapine [2] 6, 13
135 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08489 Ropinirole [4] 2, 6, 74, 309
136 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D09397 Pardoprunox [1] 6
137 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D09953 Pridopidine [3] 2, 6, 8
138 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D11839 Foslevodopa [1] 6
139 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
140 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01164 Aripiprazole [2] 6, 206
141 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
142 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07305 Piribedil [1] 6
143 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
144 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
145 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
146 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09397 Pardoprunox [1] 6
147 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
148 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
149 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00283 Clozapine [1] 6
150 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
151 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
152 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
153 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
154 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
155 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
156 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
157 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D11431 Tavapadon [1] 6
158 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
159 ABAT [7] Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
160 HTR3D [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
161 HTR3D [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [3] 6, 97, 107
162 HTR3D [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
163 F8 [1] Complement and coagulation cascades D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
164 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
165 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
166 GABBR1 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D12240 Valiloxybate [1] 6
167 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
168 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
169 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00548 Etomidate [1] 6
170 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
171 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
172 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
173 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
174 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
175 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
176 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
177 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
178 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
179 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
180 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
181 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
182 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
183 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
184 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
185 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
186 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
187 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
188 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
189 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
190 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
191 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
192 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
193 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
194 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
195 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
196 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
197 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
198 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
199 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
200 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
201 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
202 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
203 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
204 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
205 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
206 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
207 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
208 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
209 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
210 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
211 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
212 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
213 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
214 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
215 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
216 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
217 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
218 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
219 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
220 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
221 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
222 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
223 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
224 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
225 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
226 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
227 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
228 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
229 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
230 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
231 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
232 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
233 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
234 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
235 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
236 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
237 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
238 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
239 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
240 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
241 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
242 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
243 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
244 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
245 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
246 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
247 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
248 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
249 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
250 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
251 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
252 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
253 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
254 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
255 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
256 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
257 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
258 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
259 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
260 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
261 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
262 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
263 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
264 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
265 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
266 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
267 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
268 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
269 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
270 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
271 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
272 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
273 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
274 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
275 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
276 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
277 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
278 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
279 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
280 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
281 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
282 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
283 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
284 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
285 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
286 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
287 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
288 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
289 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
290 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
291 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
292 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
293 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
294 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
295 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
296 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
297 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
298 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
299 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
300 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
301 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
302 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
303 GAD1 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
304 GAD2 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
305 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08953 Nilotinib [5] 6, 8, 34, 51, 86
306 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D09664 Saracatinib [3] 6, 89, 272
307 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D04121 Exenatide [6] 6, 17, 72, 78, 193, 233
308 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D06404 Liraglutide [3] 6, 75, 193
309 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D09729 Lixisenatide [1] 6
310 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D10025 Semaglutide [1] 6
311 HTR3E [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
312 HTR3E [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [3] 6, 97, 107
313 HTR3E [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
314 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
315 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
316 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
317 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
318 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
319 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
320 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
321 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
322 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
323 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
324 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
325 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
326 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
327 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
328 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
329 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
330 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
331 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
332 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07058 Acamprosate [2] 6, 206
333 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine [4] 6, 8, 13, 127
334 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
335 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
336 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
337 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
338 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
339 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
340 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
341 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
342 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
343 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
344 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
345 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
346 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
347 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07058 Acamprosate [2] 6, 206
348 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine [4] 6, 8, 13, 127
349 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
350 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
351 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
352 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07058 Acamprosate [2] 6, 206
353 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine [4] 6, 8, 13, 127
354 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
355 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
356 NR3C1 [1] Neuroactive ligand-receptor interaction D00088 Hydrocortisone [10] 6, 41, 46, 53, 75, 78, 81, 83, 97, 299
357 NR3C1 [1] Neuroactive ligand-receptor interaction D00976 Hydrocortisone cypionate [3] 6, 81, 83
358 NR3C1 [1] Neuroactive ligand-receptor interaction D01442 Hydrocortisone succinate [3] 6, 81, 83
359 GUCY2C [2] Purine metabolism, Metabolic pathways D09355 Linaclotide [2] 6, 97
360 HCRTR1 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [2] 6, 13
361 HCRTR2 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [2] 6, 13
362 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00359 Lovastatin [11] 6, 34, 46, 79, 156, 160, 195, 206, 263, 280, 310
363 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00434 Simvastatin [21] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
364 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08492 Rosuvastatin [11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
365 HPD [5] Ubiquinone and other terpenoid-quinone biosynthesis, Tyrosine metabolism, Phenylalanine metabolism, Metabolic pathways, Biosynthesis of cofactors D05177 Nitisinone [3] 6, 164, 241
366 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07875 Doxepin [1] 6
367 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00318 Famotidine [6] 6, 46, 61, 86, 98, 107
368 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D01164 Aripiprazole [2] 6, 206
369 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D07593 Buspirone [2] 6, 51
370 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D09397 Pardoprunox [1] 6
371 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
372 HTR1B [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
373 HTR1D [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
374 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00283 Clozapine [1] 6
375 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D01164 Aripiprazole [2] 6, 206
376 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02666 Iloperidone [1] 6
377 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08456 Quetiapine [2] 6, 13
378 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D09645 Nelotanserin [1] 6
379 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02666 Iloperidone [1] 6
380 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00283 Clozapine [1] 6
381 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02578 Agomelatine [1] 6
382 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02666 Iloperidone [1] 6
383 HTR3A [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
384 HTR3A [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [3] 6, 97, 107
385 HTR3A [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
386 KCNA4 [2] Cortisol synthesis and secretion, Cushing syndrome D04127 Dalfampridine [5] 3, 4, 6, 13, 14
387 KCNC3 [1] Spinocerebellar ataxia D04127 Dalfampridine [3] 6, 13, 14
388 KCND2 [1] Serotonergic synapse D04127 Dalfampridine [3] 6, 13, 14
389 KCND3 [1] Spinocerebellar ataxia D04127 Dalfampridine [3] 6, 13, 14
390 KCNJ11 [3] Insulin secretion, GnRH secretion, Type II diabetes mellitus D00594 Repaglinide [4] 6, 21, 46, 299
391 KIT [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
392 KIT [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib [6] 2, 5, 6, 13, 46, 96
393 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02561 Moclobemide [1] 6
394 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02579 Iproniazid [1] 6
395 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08349 Phenelzine [1] 6
396 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02579 Iproniazid [1] 6
397 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D03731 Selegiline [1] 6
398 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08349 Phenelzine [1] 6
399 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08469 Rasagiline [6] 2, 5, 6, 17, 58, 66
400 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10158 Safinamide [2] 6, 17
401 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10829 Rasagiline [6] 2, 5, 6, 17, 58, 66
402 NR3C2 [1] Aldosterone-regulated sodium reabsorption D07967 Fludrocortisone [3] 6, 17, 81
403 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine [3] 5, 6, 13
404 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D04292 Galantamine [2] 6, 127
405 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
406 MTNR1A [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02578 Agomelatine [1] 6
407 MTNR1A [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon [3] 6, 8, 46
408 MTNR1A [2] Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
409 MTNR1B [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02578 Agomelatine [1] 6
410 MTNR1B [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon [3] 6, 8, 46
411 MTNR1B [2] Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
412 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole [14] 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299
413 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole [14] 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299
414 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
415 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
416 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone [5] 6, 13, 70, 226, 298
417 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
418 OPRK1 [1] Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
419 OPRK1 [1] Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
420 OPRK1 [1] Neuroactive ligand-receptor interaction D05312 Oxycodone [5] 6, 13, 70, 226, 298
421 OPRK1 [1] Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
422 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05111 Nalmefene [1] 6
423 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
424 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05312 Oxycodone [5] 6, 13, 70, 226, 298
425 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08249 Naloxone [2] 6, 226
426 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08473 Remifentanil [2] 6, 70
427 OXTR [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D00089 Oxytocin [7] 6, 72, 127, 168, 193, 206, 226
428 PDE2A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
429 PDE2A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
430 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
431 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
432 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
433 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
434 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
435 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
436 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
437 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
438 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
439 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
440 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
441 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
442 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
443 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
444 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
445 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
446 PPARG [11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
447 PPP3CA [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
448 PPP3CA [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
449 PPP3CB [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
450 PPP3CB [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
451 PPP3CC [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
452 PPP3CC [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
453 PPP3R1 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
454 PPP3R1 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
455 PPP3R2 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
456 PPP3R2 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
457 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
458 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
459 PRKAA1 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin [25] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301
460 PRKAA2 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin [25] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301
461 CACNA2D3 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
462 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
463 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
464 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
465 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
466 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
467 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
468 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
469 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
470 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
471 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00987 Cabergoline [3] 6, 74, 75
472 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D03165 Bromocriptine [2] 6, 74
473 CHRNA10 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
474 PTGS1 [5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen [15] 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337
475 PTGS2 [22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen [15] 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337
476 SCN1A [1] Dopaminergic synapse D00252 Carbamazepine [3] 6, 13, 231
477 SCN1A [1] Dopaminergic synapse D00358 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
478 SCN1A [1] Dopaminergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
479 SCN1A [1] Dopaminergic synapse D00538 Zonisamide [1] 6
480 SCN1A [1] Dopaminergic synapse D07962 Flecainide [1] 6
481 SCN1A [1] Dopaminergic synapse D08127 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
482 SCN1A [1] Dopaminergic synapse D08319 Oxybuprocaine [1] 6
483 SCN2A [1] Taste transduction D00252 Carbamazepine [3] 6, 13, 231
484 SCN2A [1] Taste transduction D00358 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
485 SCN2A [1] Taste transduction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
486 SCN2A [1] Taste transduction D00538 Zonisamide [1] 6
487 SCN2A [1] Taste transduction D07962 Flecainide [1] 6
488 SCN2A [1] Taste transduction D08127 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
489 SCN2A [1] Taste transduction D08319 Oxybuprocaine [1] 6
490 SCN3A [1] Taste transduction D00252 Carbamazepine [3] 6, 13, 231
491 SCN3A [1] Taste transduction D00358 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
492 SCN3A [1] Taste transduction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
493 SCN3A [1] Taste transduction D00538 Zonisamide [1] 6
494 SCN3A [1] Taste transduction D07962 Flecainide [1] 6
495 SCN3A [1] Taste transduction D08127 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
496 SCN3A [1] Taste transduction D08319 Oxybuprocaine [1] 6
497 SCN5A [1] Adrenergic signaling in cardiomyocytes D00252 Carbamazepine [3] 6, 13, 231
498 SCN5A [1] Adrenergic signaling in cardiomyocytes D00358 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
499 SCN5A [1] Adrenergic signaling in cardiomyocytes D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
500 SCN5A [1] Adrenergic signaling in cardiomyocytes D00538 Zonisamide [1] 6
501 SCN5A [1] Adrenergic signaling in cardiomyocytes D07962 Flecainide [1] 6
502 SCN5A [1] Adrenergic signaling in cardiomyocytes D08127 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
503 SCN5A [1] Adrenergic signaling in cardiomyocytes D08319 Oxybuprocaine [1] 6
504 SCN9A [1] Taste transduction D00252 Carbamazepine [3] 6, 13, 231
505 SCN9A [1] Taste transduction D00358 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
506 SCN9A [1] Taste transduction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
507 SCN9A [1] Taste transduction D00538 Zonisamide [1] 6
508 SCN9A [1] Taste transduction D07962 Flecainide [1] 6
509 SCN9A [1] Taste transduction D08127 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
510 SCN9A [1] Taste transduction D08319 Oxybuprocaine [1] 6
511 SLC6A1 [2] Synaptic vesicle cycle, GABAergic synapse D00332 Gabapentin [5] 6, 13, 19, 70, 298
512 SLC6A2 [1] Synaptic vesicle cycle D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
513 SLC6A2 [1] Synaptic vesicle cycle D07473 Atomoxetine [4] 6, 8, 13, 17
514 SLC6A2 [1] Synaptic vesicle cycle D07875 Doxepin [1] 6
515 SLC6A2 [1] Synaptic vesicle cycle D07880 Duloxetine [2] 6, 13
516 SLC6A2 [1] Synaptic vesicle cycle D08288 Nortriptyline [2] 6, 226
517 SLC6A2 [1] Synaptic vesicle cycle D08670 Venlafaxine [3] 6, 13, 46
518 SLC6A2 [1] Synaptic vesicle cycle D11688 Ampreloxetine [2] 6, 17
519 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D03215 Armodafinil [3] 6, 13, 84
520 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
521 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02360 Sertraline [2] 6, 206
522 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02362 Paroxetine [4] 6, 13, 46, 85
523 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram [7] 6, 8, 13, 18, 46, 98, 127
524 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07875 Doxepin [1] 6
525 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07880 Duloxetine [2] 6, 13
526 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07913 Escitalopram [4] 2, 6, 13, 46
527 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D08288 Nortriptyline [2] 6, 226
528 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D08670 Venlafaxine [3] 6, 13, 46
529 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D10184 Vortioxetine [1] 6
530 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D11688 Ampreloxetine [2] 6, 17
531 SLC10A2 [1] Bile secretion D10796 Elobixibat [1] 6
532 SLC12A2 [3] Salivary secretion, Pancreatic secretion, Vibrio cholerae infection D00247 Bumetanide [2] 6, 158
533 SLC12A2 [3] Salivary secretion, Pancreatic secretion, Vibrio cholerae infection D00331 Furosemide [2] 6, 86
534 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A [14] 2, 5, 6, 7, 13, 15, 17, 36, 47, 51, 70, 113, 149, 226
535 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D02735 Botulinum toxin type B [4] 2, 6, 13, 51
536 SNCA [3] Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases D11420 Prasinezumab [1] 6
537 SRC [42] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, Axon guidance, VEGF signaling pathway, Focal adhesion, Adherens junction, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Bacterial invasion of epithelial cells, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Bladder cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09664 Saracatinib [3] 6, 89, 272
538 SRD5A2 [3] Steroid hormone biosynthesis, Metabolic pathways, Prostate cancer D00321 Finasteride [1] 6
539 ABCC8 [3] ABC transporters, Insulin secretion, Type II diabetes mellitus D00594 Repaglinide [4] 6, 21, 46, 299
540 UGCG [2] Sphingolipid metabolism, Metabolic pathways D11633 Venglustat [3] 6, 19, 67
541 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol [24] 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
542 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00299 Dihydrotachysterol [2] 6, 85
543 TRPV1 [2] Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00250 Capsaicin [3] 6, 86, 226
544 XDH [6] Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome D00224 Allopurinol [7] 6, 46, 57, 60, 66, 96, 97
545 XDH [6] Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome D01206 Febuxostat [3] 2, 6, 13
546 CA2 [7] Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
547 CA4 [3] Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
548 CACNA1C [34] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
549 CACNA1C [34] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
550 CACNA1D [35] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
551 CACNA1D [35] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
552 CACNA1F [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
553 CACNA1F [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
554 CACNA1S [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
555 CACNA1S [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
556 CACNA2D1 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
557 VKORC1 [3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D08682 Warfarin [11] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91
558 ALDH5A1 [3] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
559 TAS1R2 [2] Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame [4] 6, 13, 67, 86
560 TAS1R3 [2] Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame [4] 6, 13, 67, 86
561 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
562 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
563 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02008 Tadalafil [7] 6, 51, 75, 84, 86, 113, 210
564 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08514 Sildenafil [17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
565 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
566 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00538 Zonisamide [1] 6
567 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
568 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00538 Zonisamide [1] 6
569 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid [14] 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
570 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00538 Zonisamide [1] 6
571 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
572 HTR3B [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
573 HTR3B [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [3] 6, 97, 107
574 HTR3B [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
575 CACNA2D2 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
576 CACNA2D4 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
577 GABBR2 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D12240 Valiloxybate [1] 6
578 SV2A [1] ECM-receptor interaction D00709 Levetiracetam [3] 6, 13, 307
579 NR1H4 [1] Bile secretion D00734 Ursodeoxycholic acid [14] 6, 8, 20, 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299